A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Phase 2
160
about 1.7 years
18+
25 sites in CA, FL, GA +12
What this study is about
Researchers are testing a treatment called Afimkibart (also known as RO7790121) for people with moderate to severe atopic dermatitis. The trial will last 604 days and involve approximately 160 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Afimkibart
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Change from Baseline in Dermatology Quality of Life Index at Week 16, Week 32 and by Visit, Percent Change from Baseline in EASI by Visit, Percent Change from Baseline in Peak Pruritus Numerical Rating Scale (NRS) Score by Visit, Percentage of Participants with Adverse Events
Dermatology